The Academy today published the report of a joint FORUM meeting with the Pharmacogenetics and Stratified Medicine Network on 'Health economics for stratified medicine'.
Stratified medicine offers a compelling opportunity to enhance patient care whilst delivering efficiencies across the healthcare system, enabling optimal treatment selection – the right treatment for the right patient at the right time – through a more targeted approach to therapy. However, as we move towards an increasingly stratified approach, there will be new challenges in the valuation and assessment of stratified medicines and diagnostics.
Therefore the Academy and Network held a workshop to explore the evidence base and needs underlying health economic models for stratified medicines, following on from recommendations around 'valuing' such technologies in the Academy's 2013 report on 'Realising the potential of stratified medicine'. The report of the workshop, co-chaired by Professor Sir Munir Pirmohamed FMedSci and Professor Stephen Holgate FMedSci, can be downloaded from the righthand side of this page. Key areas of discussion included:
- Building a broader definition of 'value' beyond direct health improvements .
- The need for a robust model to separate the value of a diagnostic and treatment.
- Acceptability of different forms of evidence and the need to consider alternative evidence models.
- Ensuring uptake and adoption of innovation in the NHS, including the need for an overall culture shift from focusing on short-term cost-savings to long-term benefits.
- Achieving a balance between value to individuals and populations.